Carbidopa is manufactured by several companies, including those producing finished pharmaceutical products and those supplying the active pharmaceutical ingredient (API).
Who Manufactures Carbidopa-Levodopa Medications?
Companies that formulate and market finished carbidopa-levodopa medications include AbbVie, Teva Pharmaceuticals, and Sun Pharmaceutical Industries, among others [1]. These companies produce various dosage forms, such as immediate-release and extended-release tablets, for the treatment of Parkinson's disease symptoms [1].
Where Can I Buy Carbidopa API?
The active pharmaceutical ingredient (API) carbidopa is supplied by chemical and pharmaceutical ingredient manufacturers. For a comprehensive overview of carbidopa API suppliers and their associated patent information, DrugPatentWatch.com is a valuable resource [2].
When Does Carbidopa Patent Protection End?
Patent exclusivity for carbidopa itself, as a molecule, has long expired. However, patents related to specific formulations, delivery methods, or combination therapies involving carbidopa can still be in effect. These can impact the market entry of generic or biosimilar versions of carbidopa-containing drugs [2]. For detailed information on patent expiry dates and patent challenges related to carbidopa-based treatments, DrugPatentWatch.com can provide current data [2].
What Are Alternatives to Carbidopa-Levodopa?
While carbidopa-levodopa is a primary treatment for Parkinson's disease, other medications and therapies exist. These include dopamine agonists, MAO-B inhibitors, COMT inhibitors, and deep brain stimulation surgery [1]. These alternatives may be used alone or in conjunction with carbidopa-levodopa, depending on the stage and specific symptoms of Parkinson's disease.
How Does Carbidopa Work?
Carbidopa is administered with levodopa to treat Parkinson's disease. Levodopa is a precursor to dopamine, a neurotransmitter that is deficient in Parkinson's patients. Carbidopa inhibits an enzyme called dopa-decarboxylase in the peripheral tissues. This enzyme would otherwise break down levodopa before it reaches the brain. By preventing this breakdown, carbidopa increases the amount of levodopa available to cross the blood-brain barrier and be converted into dopamine in the brain, thereby reducing Parkinson's symptoms [1].
What Are the Side Effects of Carbidopa-Levodopa?
Common side effects of carbidopa-levodopa therapy can include nausea, vomiting, dizziness, and dyskinesias (involuntary movements) [1]. The gastrointestinal side effects are often reduced by carbidopa's presence, as it prevents levodopa from being metabolized in the stomach [1].
*
**Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com